Communiqués Roche Holding AG Xetra

Actions

RHO

CH0012032113

Produits pharmaceutiques

Temps réel estimé Tradegate 15:00:20 08/10/2026			Varia. 5j.	Varia. 1 janv.
391,20 ^EUR	-0,86%		+3,46%	+8,53%

13:15	BofA entrevoit un relèvement des prévisions de BPA de Roche pour l’exercice 2026 grâce à l’expansion des marges et à un taux d’imposition « meilleur »	MT
11:40	Une entité de Roche et Aiforia Technologies s’associent dans le domaine des diagnostics fondés sur l’intelligence artificielle	MT

Communiqués

01/10	Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends	BU
01/10	Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions	BU
01/10	Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine	BU
30/09	Roche : fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis	PU
30/09	Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis	BU
29/09	Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon	BU
23/09	Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)	BU
22/09	Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity	BU
17/09	Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center	BU
17/09	Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study	BU
10/09	U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments	BU
20/08	Genentech Announces Manufacturing Expansion in Hillsboro, Oregon	BU
18/08	Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility	BU
20/07	Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America	PR
15/07	FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy	BU
07/07	Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC	BU
02/07	Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer	BU
30/06	FDA grants Priority Review to Roche's Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)	AQ
30/06	FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)	BU
18/06	FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma	BU
11/06	FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer	BU
04/06	Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection	PR
02/06	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	BU
01/06	Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions	BU
19/05	Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer	BU